71 related articles for article (PubMed ID: 9704000)
1. Evidence that TSG101 aberrant transcripts are PCR artifacts.
Hampl M; Hampl J; Plaschke J; Fitze G; Schackert G; Saeger HD; Schackert HK
Biochem Biophys Res Commun; 1998 Jul; 248(3):753-60. PubMed ID: 9704000
[TBL] [Abstract][Full Text] [Related]
2. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
3. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
4. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
[TBL] [Abstract][Full Text] [Related]
5. Absence of TSG101 transcript abnormalities in human cancers.
Trink B; Pai SI; Spunt SL; Raman V; Cairns P; Jen J; Gabrielson E; Sukumar S; Sidransky D
Oncogene; 1998 May; 16(21):2815-8. PubMed ID: 9652749
[TBL] [Abstract][Full Text] [Related]
6. Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues.
Willeke F; Ridder R; Bork P; Klaes R; Mechtersheimer G; Schwarzbach M; Zimmer D; Kloor M; Lehnert T; Herfarth C; von Knebel Doeberitz M
Mol Carcinog; 1998 Dec; 23(4):195-200. PubMed ID: 9869447
[TBL] [Abstract][Full Text] [Related]
7. Truncated TSG101 transcripts in human leukemia and lymphoma cell lines.
Hosokawa Y; Nagai E; Seto M
J Cancer Res Clin Oncol; 2000 Feb; 126(2):79-84. PubMed ID: 10664246
[TBL] [Abstract][Full Text] [Related]
8. Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.
Turpin E; Dalle B; de Roquancourt A; Plassa LF; Marty M; Janin A; Beuzard Y; de Thé H
Oncogene; 1999 Dec; 18(54):7834-7. PubMed ID: 10618725
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas.
Liu RT; Huang CC; You HL; Chou FF; Hu CC; Chao FP; Chen CM; Cheng JT
Oncogene; 2002 Jul; 21(31):4830-7. PubMed ID: 12101421
[TBL] [Abstract][Full Text] [Related]
10. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.
Carney ME; Maxwell GL; Lancaster JM; Gumbs C; Marks J; Berchuck A; Futreal PA
J Soc Gynecol Investig; 1998; 5(5):281-5. PubMed ID: 9773405
[TBL] [Abstract][Full Text] [Related]
11. Role of TSG101 in uterine cervix cancer.
O'Boyle JD; Proctor ML; Fong KM; Lin WM; Miller DS; Muller CY
Gynecol Oncol; 1999 Dec; 75(3):401-5. PubMed ID: 10600297
[TBL] [Abstract][Full Text] [Related]
12. Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines.
Ferrer M; López-Borges S; Lazo PA
Oncogene; 1999 Apr; 18(13):2253-9. PubMed ID: 10327071
[TBL] [Abstract][Full Text] [Related]
13. p53 induction prevents accumulation of aberrant transcripts in cancer cells.
Moyret-Lalle C; Duriez C; Van Kerckhove J; Gilbert C; Wang Q; Puisieux A
Cancer Res; 2001 Jan; 61(2):486-8. PubMed ID: 11212237
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of TSG101 in Taiwan Chinese breast cancer.
Lo YF; Chen TC; Chen SC; Chao CC
Breast Cancer Res Treat; 2000 Apr; 60(3):259-66. PubMed ID: 10930114
[TBL] [Abstract][Full Text] [Related]
15. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants.
Wagner KU; Dierisseau P; Rucker EB; Robinson GW; Hennighausen L
Oncogene; 1998 Nov; 17(21):2761-70. PubMed ID: 9840940
[TBL] [Abstract][Full Text] [Related]
16. [TSG101 and breast cancer: a correctly named tumor-suppressor gene?].
Bénard J; Ahomadégbé JC
Bull Cancer; 1997 Dec; 84(12):1141-2. PubMed ID: 9587367
[TBL] [Abstract][Full Text] [Related]
17. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation.
Oh KB; Stanton MJ; West WW; Todd GL; Wagner KU
Oncogene; 2007 Aug; 26(40):5950-9. PubMed ID: 17369844
[TBL] [Abstract][Full Text] [Related]
18. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer.
Steiner P; Barnes DM; Harris WH; Weinberg RA
Nat Genet; 1997 Aug; 16(4):332-3. PubMed ID: 9241265
[No Abstract] [Full Text] [Related]
19. Identification of cellular TSG101 protein in multiple human breast cancer cell lines.
Zhong Q; Chen CF; Chen Y; Chen PL; Lee WH
Cancer Res; 1997 Oct; 57(19):4225-8. PubMed ID: 9331081
[TBL] [Abstract][Full Text] [Related]
20. Aberrant transcripts of FHIT, TSG101 and PTEN/MMAC1 genes in normal peripheral mononuclear cells.
Wang NM; Chang JG; Liu TC; Lin SF; Peng CT; Tsai FJ; Tsai CH
Int J Oncol; 2000 Jan; 16(1):75-80. PubMed ID: 10601551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
